Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group
about
Optimal usage of the GnRH antagonists: a review of the literatureGonadotrophin-releasing hormone antagonists for assisted reproductive technologyGonadotrophin-releasing hormone antagonists for assisted reproductive technologyGonadotrophin-releasing hormone antagonists for assisted conceptionDifferent ovarian stimulation protocols for women with diminished ovarian reserveThe role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and preventionOvarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatmentComparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: A systematic review and meta-analysisSerum Oestradiol Pattern during Coasting is Different in Antagonist Cycles Compared with Long Agonist Cycles in In Vitro FertilisationDoes the Ovarian Stimulation Phase Length Predict In vitro Fertilization Outcomes?Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis.Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.Gonadotropin-releasing hormone antagonists implications for oocyte quality and uterine receptivity.Comparison of ovulation induction protocols after endometrioma resection.Cumulus cells gene expression profiling in terms of oocyte maturity in controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist.Advances in the treatment of precocious puberty.Cetrorelix in the treatment of female infertility and endometriosis.Monitoring during gonadotrophin-releasing hormone antagonist protocols.Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation.Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trialSafety of GnRH agonists and antagonists.Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non-obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI.Maximum basal FSH predicts reproductive outcome better than cycle-specific basal FSH levels: waiting for a "better" month conveys limited retrieval benefitsA Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran.The role of luteinizing hormone activity in controlled ovarian stimulation.Emerging drugs in assisted reproduction.A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patientsLate follicular progesterone to estradiol ratio is not influenced by protocols or gonadotropins used.Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.Luteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocolThe effects of GnRH antagonist on the endometrium of normally menstruating women.Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation.GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol.Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?Outcome of frozen-thawed blastocysts derived from gonadotropin releasing hormone agonist or antagonist cycles.A comparative study on oxidative and antioxidative markers of serum and follicular fluid in GnRH agonist and antagonist cyclesOvarian feedback, mechanism of action and possible clinical implications.
P2860
Q21245566-C1EB2BA7-1380-4A82-9F8C-B2AB2F55C2DAQ24185849-50E30716-FD06-4F12-9012-E5F02CBFA380Q24234608-B0DEB22E-1070-4F12-A012-1DA2CFA23EFFQ24245006-82E36B6C-6D81-48BB-98EF-1FB574CB3C82Q24634342-07254E0E-3618-4242-B994-E61253CB1E44Q24816913-280CB547-6B43-4912-BED9-5168C99ACBAEQ26827593-D775D814-7D51-4FF9-8274-46487C08DC29Q28345695-AD3E09D8-F5CC-4B3A-AB8F-2C5E3CA8B9EDQ33596777-33AF8F83-C445-44FD-9420-C1FC65FBE98CQ33974030-B3EC520F-E77B-4320-A68C-48551DEFE0B6Q34007031-AB47BAD3-388D-46E1-9123-AD633B5D6641Q34172380-EB376297-29CE-4B94-94D2-8D4591DA662EQ34201717-3820780B-AD76-46E6-BFC9-414B533C0A5BQ34397296-92CA6DD5-17FD-4102-86A3-07ADE2B3830BQ34401295-337858C4-0101-49BB-BD1D-08C244BC15DEQ34451981-1742CFCA-AB93-4513-8DF5-6F7C18DA9AD5Q34481681-CD701BEE-57BF-4713-9589-4C39C24F06E1Q34571550-810BE1E4-566E-4798-8511-4926DFB13FA2Q34591670-F8BA3A6B-9700-4104-A360-FEA79AB748C5Q34656033-62007884-4897-4D80-A208-6033AF256EC1Q35094469-5C4815CC-33B2-4362-B7FA-6393BA895E89Q35609748-AD0711F7-EE69-4F0E-A2FC-67A3D4511AE8Q35925814-F1814B64-E938-402C-A985-ED566B59CFA4Q35953736-BB144227-17E4-41AD-80F0-378CC87A178BQ35995836-D4DA9230-F383-47A1-BDE9-87BD15F75B48Q36074736-F720FF09-54DA-428A-9184-AC05D3F96939Q36091586-A2138E9C-C638-4072-B3C2-A4C8F9B2E28DQ36150659-87704CC4-C426-436A-8527-0599D4BFA334Q36159645-C7D60D03-A9C7-4E76-AA8E-F73C43DEE134Q36249259-F4876240-7CF2-4EDE-8F50-C1B5F61816C6Q36256701-361A703F-8098-4E94-89EA-C0CC19ED5838Q36268229-F97C80EA-3252-48DE-B9CA-39CEF894FE99Q36268361-3D93492C-3C94-43F2-8F8E-1822C710D15CQ36268633-34214D5E-1CBD-4B29-ACFE-B7EEE8DDA8D3Q36269371-62F5856E-23A8-4EED-94D1-EE11837BC1FEQ36308688-6A5F015A-2716-44EB-BA1D-51185A125365Q36423212-9FB8AD2A-C11F-49C4-9348-F9EB183BC534Q36423226-BCAB6BCB-9AB8-4F9C-94E6-009CF749453EQ36434666-4FC17CCE-0206-4AC9-A625-83BB207C321BQ36467616-0D41A55E-1DF8-49CF-8626-41C7B476E23B
P2860
Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@ast
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en-gb
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@nl
type
label
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@ast
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en-gb
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@nl
prefLabel
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@ast
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en-gb
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@nl
P2093
P3181
P356
P1433
P1476
Ovarian stimulation with HMG: ...... uropean Cetrorelix Study Group
@en
P2093
H Riethmüller-Winzen
K Diedrich
R E Felberbaum
P304
P3181
P356
10.1093/HUMREP/15.3.526
P407
P50
P577
2000-03-01T00:00:00Z